Gemcitabine and capecitabine with or without telomerase peptide vaccine GV1001 in patients with locally advanced or metastatic pancreatic cancer (TeloVac): an open-label, randomised, phase 3 trial

Gary Middleton(University of Birmingham), John P. Neoptolemos(University of Liverpool), Tom Roques(Norfolk and Norwich University Hospital), Stephen Falk(At Bristol), Jonathan Wadsley(Weston Park Cancer Centre), Srinivasan Madhusudan(Nottingham University Hospitals NHS Trust), Angus Robinson(Royal Sussex County Hospital), Charlotte Rawcliffe(University of Liverpool), Karen McAdam(Peterborough City Hospital), Tamas Hickish(Southampton General Hospital), William Greenhalf(University of Liverpool), Angel Garcia-Alonso(Glan Clwyd Hospital), Nick Wadd(South Tees Hospitals NHS Foundation Trust), JEFF EVANS(University of Glasgow), David Propper(St Bartholomew's Hospital), Dean J. Naisbitt(Cancer Research UK), Timothy Iveson(University Hospital Southampton NHS Foundation Trust), David Cunningham(Royal Marsden NHS Foundation Trust), Victoria Shaw(University of Liverpool), Pippa Corrie(Cambridge University Hospitals NHS Foundation Trust), Caroline Archer(Queen Alexandra Hospital), Juan W. Valle(The Christie NHS Foundation Trust), Alan Anthoney(St James's University Hospital), Gemma Nanson(Cancer Research UK), Trevor F. Cox(University of Liverpool), Paul J. Ross(Guy's and St Thomas' NHS Foundation Trust), William P. Steward(The Christie Hospital), Paul Silcocks(University of Liverpool), Mark Harrison(Hillingdon Hospitals NHS Foundation Trust), Martin Eatock(Queen's University Belfast), Fareeda Y. Coxon(Newcastle upon Tyne Hospitals NHS Foundation Trust), M. Nicolson, Eithne Costello(University of Liverpool)
The Lancet Oncology
June 19, 2014
Cited by 374


Related Papers